Cytek Biosciences (CTKB) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 7% year-over-year to $51.5 million, with strong growth in EMEA and APAC and robust service revenue from an expanding installed base.

• Net income for Q3 2024 was $0.9 million, reversing a net loss of $6.5 million in Q3 2023, driven by improved operating results, foreign exchange gains, and a tax benefit.

• The global installed base expanded to 2,821 instruments, including Amnis and Guava units from the Luminex acquisition.

• Cytek Cloud user base more than doubled to over 13,600 users since the start of the year.

• Completed the acquisition of FlowCEL assets in October 2024 and continued investment in R&D and commercial infrastructure.

Financial highlights

• Q3 2024 revenue was $51.5M (+7% YoY, +10% sequentially); YTD revenue at $143.0M (+6% YoY).

• GAAP gross profit was $29M, with a gross margin of 56% (down from 57% prior year); adjusted gross margin reached 60%.

• Adjusted EBITDA was $7.6M in Q3 2024, up from $3.7M in Q3 2023.

• Operating expenses were $33.3M, down 2% sequentially and 1% year-over-year; R&D expenses for nine months were $29.7M (down 11% YoY).

• Cash and marketable securities totaled $277.8M as of September 30, 2024, despite $12.1M in share repurchases.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $203M–$210M, representing 5%–9% growth over 2023.

• Expects a GAAP net loss in the single-digit millions for 2024, with a goal of positive net income going forward.

• Anticipates continued positive cash flow from operations in 2024.

• Q4 expected to follow normal seasonal pattern, with about 30% of annual revenue typically realized in Q4.

• Management expects expenses to remain relatively flat, focusing on new product development and revenue growth.